Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12549987 | 0.82 | KEAP1 (0.58) | MAPTPOLBTP53KMT2AMEN1 | |
| SCHEMBL62700 | 0.82 | MAPT (0.72) | MAPTTP53TSHR | |
| SCHEMBL12077597 | 0.79 | NAMPT (0.71) | NAMPTKMT2AMEN1 | |
| SCHEMBL1287354 | 0.79 | POLB (0.65) | MAPTPOLBNAMPTKMT2AMEN1 | |
| SCHEMBL3850206 | 0.78 | POLB (0.72) | MAPTPOLBNAMPTPKMTSHR | |
| SCHEMBL119461 | 0.78 | POLB (0.72) | MAPTPOLBNAMPTPKMTSHR | |
| SCHEMBL20981410 | 0.77 | ALDH1A1 (0.68) | MAPTPOLBTP53NAMPTKMT2A | |
| SCHEMBL533533 | 0.77 | NAMPT (0.53) | MAPTNAMPTKMT2AMEN1PKM | |
| SCHEMBL1278961 | 0.76 | TSHR (0.80) | MAPTPOLBNAMPTKMT2ATSHR | |
| SCHEMBL20981395 | 0.76 | TSHR (0.80) | MAPTPOLBNAMPTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | MAPT 2242/4885POLB 4630/4885TP53 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.